Connect Biopharma Holdings Ltd (CNTB) stock
CNTBNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.58−0.06 (-9.98%)
Close on Nov 17, 2026Market cap $36.45MP/E –Yield –
Connect Biopharma ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Connect Biopharma's ebitda for the twelve months ending Jun 30, 2026 was -$69.73M. For fiscal 2025 it was -$57.37M. The highest annual figure on record is -$21.79M in fiscal 2024.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$57.37M | – |
| FY2024 | Dec 31, 2024 | -$21.79M | – |
| FY2023 | Dec 31, 2023 | -$68.34M | – |
| FY2022 | Dec 31, 2022 | -$118.29M | – |
| FY2021 | Dec 31, 2021 | -$97.47M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$17.44M | – |
| Q1 FY2026 | Mar 31, 2026 | -$19.44M | – |
| Q4 FY2025 | Dec 31, 2025 | -$15.35M | – |
| Q3 FY2025 | Sep 30, 2025 | -$17.50M | – |
| Q2 FY2025 | Jun 30, 2025 | -$13.25M | -196.0% |
| Q1 FY2025 | Mar 31, 2025 | -$11.27M | – |
| Q4 FY2024 | Dec 31, 2024 | -$9.46M | – |
| Q3 FY2024 | Sep 30, 2024 | -$13.67M | – |
| Q2 FY2024 | Jun 30, 2024 | $13.81M | – |
| Q1 FY2024 | Mar 31, 2024 | -$12.47M | – |
See a number that looks wrong?